vTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest Up 34.6% in August

vTv Therapeutics Inc. (NASDAQ:VTVT) was the target of a large increase in short interest during the month of August. As of August 15th, there was short interest totalling 38,100 shares, an increase of 34.6% from the July 31st total of 28,300 shares. Approximately 3.0% of the company’s shares are short sold. Based on an average trading volume of 24,900 shares, the short-interest ratio is currently 1.5 days.

vTv Therapeutics Price Performance

Shares of VTVT stock traded up $0.51 during mid-day trading on Thursday, hitting $15.69. The stock had a trading volume of 6,238 shares, compared to its average volume of 40,825. The firm has a market capitalization of $47.23 million, a P/E ratio of -1.77 and a beta of 0.65. The firm’s 50-day moving average is $17.75 and its two-hundred day moving average is $19.96. vTv Therapeutics has a 12-month low of $7.38 and a 12-month high of $30.99.

Wall Street Analyst Weigh In

Separately, StockNews.com cut vTv Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, May 13th.

Hedge Funds Weigh In On vTv Therapeutics

An institutional investor recently bought a new position in vTv Therapeutics stock. Baker BROS. Advisors LP acquired a new position in shares of vTv Therapeutics Inc. (NASDAQ:VTVT) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 97,314 shares of the biotechnology company’s stock, valued at approximately $2,290,000. Baker BROS. Advisors LP owned about 3.23% of vTv Therapeutics at the end of the most recent quarter. 17.51% of the stock is currently owned by institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.